Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ology Bioservices Inks $27M DoD Deal | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ology Bioservices Inks $27M DoD Deal

To adapt Veroplex cell platform for rapid response to viral threats for Department of Defense

By: Contract Pharma

Contract Pharma Staff

The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices, a biologics contract development and manufacturing organization (CDMO), to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases.
 
“The Veroplex platform has the possibility to allow rapid vaccine development for many potential emerging viral infectious diseases,” said Peter Khoury, president and chief executive officer, Ology Bioservices. “There is solid evidence that this Vero cell line, when combined with recent innovations in vaccine manufacturing technology, may be valuable in quickly manufacturing vaccines and other biologics in a very small footprint.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics